Quarterly insights: Internet of Things
CES now a key B2B IoT forum: Six themes from the 2024 show
CES 2024 featured an abundance of telematics hardware providers, video telematics solution providers, hardware-agnostic end-to-end IoT solutions and many more types of B2B IoT companies. We expect CES to continue to rise in prominence as the most productive trade forum for B2B IoT companies.
Based on our meetings and our observations on the show floor, we identified key themes for B2B IoT in six areas: artificial intelligence, energy harvesting technology, cameras, hardware strategies, sensor fusion, and robotics.
We discuss each of these areas and highlight relevant companies.
TABLE OF CONTENTS
- CES increasingly preferred over MWC
- AI everywhere, as expected
- Energy harvesting for indoor applications a major coming trend
- Camera solutions in abundance, including computer vision; bodycams of interest to vendors to differentiate offerings
- Hardware agnostic solutions becoming more common; potential to become norm in some markets
- Sensor fusion a reasonable approach to differentiate, likely to become common
- Smaller designs, creative business models suggest wider robotics adoption on horizon
- Looking ahead to future CES shows
- IoT index strength broadens slightly
- IoT M&A: Notable transactions include MiX Telematics, IPVideo and Cubic Telecom
- IoT private placements: Notable transactions include BusPatrol, Utility and Terminal
CES increasingly preferred over MWC
Clinical trials are the backbone of medical research, serving as a key bridge between drug development and patient care. As we have discussed in our previous reports, clinical trials are expensive and time consuming, and any delay pushes out the timeline for potential approval, meaning lost opportunities to improve patients’ lives and unrecoverable revenue. Supplying clinical trials with trial therapies, or investigational medicinal products (IMPs), is a pivotal part of the clinical trial process that can affect trials’ success, cost and speed. The critical nature of clinical trial supply management became especially apparent during the pandemic, which highlighted supply chain weaknesses in areas such as third-party logistics, forecasting, inventory visibility and staffing. With this in mind, pharmaceutical companies are increasingly turning to technology-based solution providers to handle some or all of their clinical trial supply needs.
Indeed, despite the diversity of business models and technologies represented at CES outside of B2B IoT, we were able to meet with dozens of B2B IoT companies, counting both exhibitors and those just attending, across the IoT value chain. They ranged in focus from hardware to network connectivity to software, encompassing both point and end-to-end solution providers and a wide range of vertical markets and use cases. CES 2024 proved to be abundant with telematics hardware providers, video telematics solution providers, hardware-agnostic end-to-end IoT solutions and many more types of B2B IoT companies. We expect CES to continue to rise in prominence as the most productive forum for B2B IoT companies.
Based on our meetings and our observations on the show floor, we identified six key themes for B2B IoT. We discuss them briefly below and plan to explore one or two of them in detail in future reports.
Request full report
To access the full report, please provide your contact information in the form below. Thank you for your interest in First Analysis research.